Federica Del Chierico

Dr. Federica Del Chierico

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2016 in Hepatology
Verified
Journal Article
Open access
PDF file
FCFederica Del Chierico
Federica Del Chierico
VNValerio Nobili
Valerio Nobili
PVPamela Vernocchi
Pamela Vernocchi
ARAlessandra Russo
Alessandra Russo
CSCristiano De Stefanis
Cristiano De Stefanis
LPLorenza Putignani
Lorenza Putignani
There is evidence that nonalcoholic fatty liver disease (NAFLD) is affected by gut microbiota. Therefore, we investigated its modifications in pediatric NAFLD patients using targeted metagenomics and metabolomics. Stools were collected from 61 consecutive patients diagnosed with nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), or obesity and 54 healthy controls (CTRLs), matched in a case‐control fashion. Operational taxonomic units were pyrosequenced targeting 16S ribosomal RNA and volatile organic compounds determined by solid‐phase microextraction gas chromatography‐mass spectrometry. The α‐diversity was highest in CTRLs, followed by obese, NASH, and NAFL patients; and β‐diversity distinguished between patients and CTRLs but not NAFL and NASH. Compared to CTRLs, in NAFLD patients Actinobacteria were significantly increased and Bacteroidetes reduced. There were no significant differences among the NAFL, NASH, and obese groups. Overall NAFLD patients had increased levels of Bradyrhizobium, Anaerococcus, Peptoniphilus, Propionibacterium acnes, Dorea, and Ruminococcus and reduced proportions of Oscillospira and Rikenellaceae compared to CTRLs. After reducing metagenomics and metabolomics data dimensionality, multivariate analyses indicated a decrease of Oscillospira in NAFL and NASH groups and increases of Ruminococcus, Blautia, and Dorea in NASH patients compared to CTRLs. Of the 292 volatile organic compounds, 26 were up‐regulated and 2 down‐regulated in NAFLD patients. Multivariate analyses found that combination of Oscillospira, Rickenellaceae, Parabacteroides, Bacteroides fragilis, Sutterella, Lachnospiraceae, 4‐methyl‐2‐pentanone, 1‐butanol, and 2‐butanone could discriminate NAFLD patients from CTRLs. Univariate analyses found significantly lower levels of Oscillospira and higher levels of 1‐pentanol and 2‐butanone in NAFL patients compared to CTRLs. In NASH, lower levels of Oscillospira were associated with higher abundance of Dorea and Ruminococcus and higher levels of 2‐butanone and 4‐methyl‐2‐pentanone compared to CTRLs. Conclusion: An Oscillospira decrease coupled to a 2‐butanone up‐regulation and increases in Ruminococcus and Dorea were identified as gut microbiota signatures of NAFL onset and NAFL‐NASH progression, respectively. (Hepatology 2017;65:451‐464)

17 April 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
SBSherrie Bhoori
Sherrie Bhoori
CCChiara Castelli
Chiara Castelli
LPLorenza Putignani
Lorenza Putignani
LRLicia Rivoltini
Licia Rivoltini
VMVincenzo Mazzaferro
Vincenzo Mazzaferro

26 July 2016 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
PVPamela Vernocchi
Pamela Vernocchi
FCFederica Del Chierico
Federica Del Chierico
LPLorenza Putignani
Lorenza Putignani
The gut microbiota is composed of a huge number of different bacteria, which produce a large amount of compounds playing a key role in microbe selection and in the construction of a metabolic signaling network. The microbial activity is affected by environmental stimuli leading to the generation of a wide number of compounds, which influence the host metabolome and human health. Indeed, metabolic profiles related to the gut microbiota can offer deep insights on the impact of lifestyle and dietary factors on chronic and acute diseases. Metagenomics, metaproteomics and metabolomics are some of the meta-omics approaches to study the modulation of the gut microbiota. Metabolomic research applied to biofluids allows to: define the metabolic profile; identify and quantify classes and compounds of interest; characterize small molecules produced by intestinal microbes; and define the biochemical pathways of metabolites. Mass spectrometry and nuclear magnetic resonance spectroscopy are the principal technologies applied to metabolomics in terms of coverage, sensitivity and quantification. Moreover, the use of biostatistics and mathematical approaches coupled with metabolomics play a key role in the extraction of biologically meaningful information from wide datasets. Metabolomic studies in gut microbiota-related research have increased, focusing on the generation of novel biomarkers, which could lead to the development of mechanistic hypotheses potentially applicable to the development of nutritional and personalized therapies.

27 March 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
VBValerio Baldelli
Valerio Baldelli
FSFRANCO SCALDAFERRI
FRANCO SCALDAFERRI
LPLorenza Putignani
Lorenza Putignani
FCFederica Del Chierico
Federica Del Chierico
Inflammatory bowel diseases (IBDs) are a group of chronic gastrointestinal inflammatory diseases with unknown etiology. There is a combination of well documented factors in their pathogenesis, including intestinal microbiota dysbiosis. The symbiotic microbiota plays important functions in the host, and the loss of beneficial microbes could favor the expansion of microbial pathobionts. In particular, the bloom of potentially harmful Proteobacteria, especially Enterobacteriaceae, has been described as enhancing the inflammatory response, as observed in IBDs. Herein, we seek to investigate the contribution of Enterobacteriaceae to IBD pathogenesis whilst considering the continuous expansion of the literature and data. Despite the mechanism of their expansion still remaining unclear, their expansion could be correlated with the increase in nitrate and oxygen levels in the inflamed gut and with the bile acid dysmetabolism described in IBD patients. Furthermore, in several Enterobacteriaceae studies conducted at a species level, it has been suggested that some adherent-invasive Escherichia coli (AIEC) play an important role in IBD pathogenesis. Overall, this review highlights the pivotal role played by Enterobacteriaceae in gut dysbiosis associated with IBD pathogenesis and progression.

14 April 2014 in Pediatric Research
Verified
Journal Article
Closed access
LPLorenza Putignani
Lorenza Putignani
FCFederica Del Chierico
Federica Del Chierico
APAndrea Petrucca
Andrea Petrucca
PVPamela Vernocchi
Pamela Vernocchi
BDBruno Dallapiccola
Bruno Dallapiccola

Verified
Journal Article
Open access
PDF file
PVPamela Vernocchi
Pamela Vernocchi
FCFederica Del Chierico
Federica Del Chierico
LPLorenza Putignani
Lorenza Putignani
The human gut contains trillions of microbes that play a central role in host biology, including the provision of key nutrients from the diet. Food is a major source of precursors for metabolite production; in fact, diet modulates the gut microbiota (GM) as the nutrients, derived from dietary intake, reach the GM, affecting both the ecosystem and microbial metabolic profile. GM metabolic ability has an impact on human nutritional status from childhood. However, there is a wide variability of dietary patterns that exist among individuals. The study of interactions with the host via GM metabolic pathways is an interesting field of research in medicine, as microbiota members produce myriads of molecules with many bioactive properties. Indeed, much evidence has demonstrated the importance of metabolites produced by the bacterial metabolism from foods at the gut level that dynamically participate in various biochemical mechanisms of a cell as a reaction to environmental stimuli. Hence, the GM modulate homeostasis at the gut level, and the alteration in their composition can concur in disease onset or progression, including immunological, inflammatory, and metabolic disorders, as well as cancer. Understanding the gut microbe–nutrient interactions will increase our knowledge of how diet affects host health and disease, thus enabling personalized therapeutics and nutrition.